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Studies of acute kidney injury usually lack data on pre-
admission kidney function and often substitute an inpatient
or imputed serum creatinine as an estimate for baseline renal
function. In this study, we compared the potential error
introduced by using surrogates such as (1) an estimated
glomerular filtration rate of 75ml/min per 1.73m2 (suggested
by the Acute Dialysis Quality Initiative), (2) a minimum
inpatient serum creatinine value, and (3) the first admission
serum creatinine value, with values computed using
pre-admission renal function. The study covered a
12-month period and included a cohort of 4863 adults
admitted to the Vanderbilt University Hospital. Use of both
imputed and minimum baseline serum creatinine values
significantly inflated the incidence of acute kidney injury
by about half, producing low specificities of 77–80%.
In contrast, use of the admission serum creatinine value as
baseline significantly underestimated the incidence by about
a third, yielding a low sensitivity of 39%. Application of any
surrogate marker led to frequent misclassification of patient
deaths after acute kidney injury and differences in both
in-hospital and 60-day mortality rates. Our study found that
commonly used surrogates for baseline serum creatinine
result in bi-directional misclassification of the incidence
and prognosis of acute kidney injury in a hospital setting.
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Acute kidney injury (AKI) is a common cause of morbidity
and mortality in the acutely ill, and is an important
risk factor for progression to end-stage renal disease.1–5
Recent studies indicate that even modest degrees of renal
injury are associated with poor outcomes in hospitalized
patients.6,7 With the introduction of the RIFLE and Acute
Kidney Injury Network (AKIN) consensus criteria,8,9 studies
have attempted to standardize the diagnosis and disease
severity of AKI based on absolute or fractional increases in
serum creatinine (SCr) or progressive degrees of oliguria.
Although such standardization has helped to provide
meaningful comparisons of disease incidence and prognosis
across different hospital settings, current consensus criteria do
not uniformly define AKI that begins before hospital admis-
sion. As these patients are at high risk for further AKI
development after admission, classification of AKI remains
challenging because serum creatinine measurements, preferably
reflecting stable kidney function before the inciting illness, are
often missing. In the absence of a standard method to
accommodate missing values, investigators performing popula-
tion-based AKI studies have used a variety of surrogate
measures. These have included substituting the admission
creatinine value,10–12 substituting a minimum creatinine value
during the hospital stay,7,13,14 or calculating a serum creatinine
value based on an imputed estimated glomerular filtration rate
(eGFR) of 75 ml/min per 1.73 m2 as initially recommended by
the Acute Dialysis Quality Initiative.3,4,15,16 The potential error
introduced by using these surrogates is unknown. We
hypothesized that commonly used surrogates for baseline renal
function would substantially misclassify AKI incidence, severity,
and prognosis when compared with a known outpatient
baseline. We examined the impact of using each surrogate
within a cohort of patients admitted to a tertiary care academic
medical center during a 12-month period.
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RESULTS
Subject characteristics
A total of 4863 qualifying adult patients with at least one
outpatient nonemergency room serum creatinine measure-
ment between 7 and 365 days before admission and two or
more inpatient serum creatinine measurements during the
first 7 days of hospitalization were admitted to the Vanderbilt
University Hospital between 10 January 2007 and 10 January
2008. A total of 10,477 patients who had no outpatient serum
creatinine values within the Vanderbilt University Medical
Center (VUMC) database within a year before admission and
2996 patients with only one inpatient serum creatinine value
were excluded. The median number of outpatient creatinine
measurements available per patient was 2 (interquartile range
(IQR): 1–4), with a median measurement time of 41 days
(IQR: 17–120) before hospital admission. The mean age of
the study population was 59.6±16.9 years. Overall, there was
a slight female preponderance (51.1%), and the majority of
subjects were identified as Caucasian (81.3%). Subjects were
assigned to internal medicine-affiliated services in 71.8% of
the admissions, surgical-based services in 26.6% of admis-
sions, and to other services for the remaining 1.6% of the
subjects. Admission or transfer to a critical care unit occurred
in 19.0% of the cohort during the first 7 days of
hospitalization.
Table 1 compares the baseline demographic characteristics
and comorbidities of patients with and without AKI in the
first 7 days of hospitalization using the preadmission
outpatient serum creatinine as a baseline. Subjects developing
AKI were more likely to be older, male, nonwhite, and to
carry a diagnosis of chronic kidney disease, diabetes mellitus,
hypertension, coronary artery disease, congestive heart
failure, and peripheral vascular disease (Po0.05). Patients
with AKI also tended to have a higher median outpatient
baseline serum creatinine 1.13 (IQR: 0.9–1.5) mg/dl and lower
corresponding baseline eGFR 63.6 (IQR: 45.7–85.5) than
those without AKI (median SCr 1.00 (IQR: 0.83–1.23) and
eGFR 72.5 (IQR: 56.1–90.0)) (Po0.05).
Baseline renal function assessment using different
approaches
Table 2 compares the three methods of estimating baseline
serum creatinine and corresponding eGFR values with a
known outpatient baseline creatinine. Median known out-
patient baseline serum creatinine and eGFR were 1.03 (IQR:
0.85–1.30) mg/dl and 70.6 (IQR: 53.2–88.8) ml/min per
1.73 m2, respectively. By comparison, imputing an eGFR of
75 ml/min per 1.73 m2 for the cohort resulted in a similar
median creatinine value, but a significantly lower range of
distribution (median SCr 1.01 (IQR: 0.83–1.07) mg/dl;
Po0.001). Similarly, the minimum serum creatinine ob-
served during the first 7 days of hospitalization was lower
than the known outpatient baseline creatinine (median 0.89
(IQR: 0.72–1.15) mg/dl; Po0.001) and gave a correspond-
ingly higher estimated eGFR (median 82.7 (IQR:
60.6–107.5) ml/min per 1.73 m2). Finally, using the admission
serum creatinine led to a higher estimate of baseline
creatinine (median 1.04 (IQR: 0.83–1.37) mg/dl; Po0.001)
and lower eGFR (69.8 (IQR: 49.4–91.1) ml/min per 1.73 m2;
P¼ 0.014).
AKI incidence and staging according to baseline definition
Overall, 1241 subjects (25.5%) experienced AKI using known
outpatient baseline serum creatinine values, with 18.9%
(N¼ 920) classified as AKIN Stage I, 3.5% (N¼ 169) as
AKIN Stage II, and 3.1% (N¼ 152) as AKIN Stage III within
7 days of hospitalization. Table 3a–c shows the frequency
and direction of AKI misclassification relative to the
known outpatient baseline by using the study’s alternative
approaches to determine baseline kidney function.
Table 1 | Baseline clinical data grouped according to the maximal AKIN status achieved within 7 days of hospital admissiona
No AKI
(N=3622), 74.5%
AKI
(N=1241), 25.5% P-value
Age 59.3±17.0 60.5±16.3 0.038
Men, n (%) 1730 (47.8%) 648 (52.3%) 0.006
White, n (%) 2987 (82.5%) 967 (77.9%) o0.001
Diabetes mellitus, n (%) 887 (24.5%) 430 (34.7%) o0.001
Chronic kidney disease, n (%) 1196 (33.0%) 632 (51.0%) o0.001
Hypertension, n (%) 1883 (52.0%) 757 (61.0%) o0.001
Coronary disease, n (%) 989 (27.3%) 417 (33.6%) o0.001
Congestive heart failure, n (%) 658 (18.2%) 369 (29.7%) o0.001
Peripheral vascular disease, n (%) 299 (8.3%) 156 (12.6%) o0.001
Admission service o0.001
Medical, n (%) 2555 (70.6%) 935 (75.3%)
Surgical, n (%) 999 (27.6%) 297 (23.9%)
Other, n (%) 68 (1.9%) 9 (0.7%)
ICU within 7 days of admission, n (%) 556 (15.4%) 368 (29.7%) o0.001
Median (IQR) baseline creatinine (mg/dl) 1.00 (0.83–1.23) 1.13 (0.9–1.5) o0.001
Baseline estimated glomerular filtration rate, (IQR)ml/min per 1.73m2 72.5 (56.1–90.0) 63.6 (45.7–85.5) o0.001
Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; ICU, intensive care unit; IQR, interquartile range.
aAccording to the known outpatient serum creatinine measurement.
P-values of o0.05 denote statistical significance.
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Compared with using a known outpatient baseline serum
creatinine value, applying an imputed serum creatinine
increased the overall AKI incidence to 38.3% (N¼ 1863;
Po0.001) (Table 3a). With respect to AKIN staging, 29.5%
(N¼ 1432) of subjects were misclassified, with 24.5% being
staged into a higher degree of injury and 5.0% being classified
into a lower stage of injury. Application of an imputed
baseline yielded a sensitivity of 84.2% and a specificity of
77.4% for the diagnosis of AKI.
Use of the minimum inpatient creatinine as a baseline also
led to an overestimation of AKI incidence compared with a
known outpatient value (35.9 versus 25.5%; Po0.001). A
total of 24.0% (N¼ 1178) of patients were misclassified, with
17.9% restaged into higher AKIN severity whereas 6.3% were
Table 2 | Baseline serum creatinine and eGFR using various approaches compared to the known outpatient baseline
Approach SCr (mg/dl) P-value
eGFR
(ml/min per 1.73m2) P-value
Known outpatient baseline 1.03 (0.85–1.30) 70.6 (53.2–88.8)
Single imputation 75ml/min 1.01 (0.83–1.07) o0.001 75.0 o0.001
Minimum inpatient 0.89 (0.72–1.15) o0.001 82.7 (60.6–107.5) o0.001
Admission 1.04 (0.83–1.37) o0.001 69.8 (49.4–91.1) 0.014
Abbreviations: eGFR, estimated glomerular filtration rate; IQR, interquartile range; SCr, serum creatinine.
Values are presented as median (IQR) with comparisons made using known baseline SCr as the reference value.
P-values of o0.05 denote statistical significance.
Table 3 | (a–c) Frequency and direction of AKIN misclassification
Abbreviation: AKIN, Acute Kidney Injury Network; SCr, serum creatinine.
Interior cells show the number of subjects staged using a baseline estimation technique (top row of each table) and a known outpatient baseline (left column of each table).
White boxes forming a diagonal line indicate agreement between the two approaches. Shaded boxes above the diagonal white boxes represent the number of subjects
misclassified to a higher AKIN stage. Shaded boxes below the diagonal white boxes represent the number of subjects misclassified to a lower AKIN stage.
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re-staged to a lower AKIN severity (Table 3b). Overall, using
a minimum inpatient creatinine value as a baseline yielded a
sensitivity of 81.7% and a specificity of 79.8% for the
diagnosis of AKI.
In contrast, using the first admission creatinine value as a
baseline led to a reduced estimate of AKI incidence relative to
a known outpatient baseline (13.7 versus 25.5%; Po0.001)
(Table 3c). Overall, 4.3% of patients were reclassified as
having more severe AKIN stage, and 17.0% of patients were
reclassified into a less severe AKIN stage. Substituting a first
admission creatinine value yielded a sensitivity of 38.9% and
a specificity of 94.9%.
In-hospital and 60-day mortality
Among all patients, 94 in-hospital deaths occurred and an
additional 269 deaths occurred within 60 days of discharge.
Figure 1a and b shows the mortality rates after AKI as
diagnosed by surrogate baseline methods compared with a
known outpatient baseline. In 1241 patients developing AKI
using our study reference standard, in-hospital and 60-day
mortality rates were 4.8% (95% CI: 3.6–6.1%) and 13.1%
(95% CI: 11.3–15.1%), respectively. Using any surrogate led
to incremental increases in mortality rates with higher AKIN
stage. Differences between mortality rates were apparent
between methods, although many of the rate estimates had
overlapping confidence intervals. In general, use of an
imputed or minimum serum creatinine value as a baseline
estimated a lower mortality rate than the study reference
standard. In contrast, using an admission creatinine as a
baseline estimated a mortality rate higher than the study
reference standard, particularly for AKIN stage II.
Among deaths occurring within 60 days, use of surrogate
baseline serum creatinine values frequently misclassified
whether the death followed AKI. For example, using an
imputed eGFR of 75 ml/min per 1.73 m2 or a minimum
inpatient serum creatinine value led to a 21.8 and 24.8%
misclassification rate, respectively. The majority of these
errors were generated when deaths were misclassified as
following AKI when no AKI was diagnosed using the study
reference standard. In contrast, use of an admission serum
creatinine value as a baseline misclassified 28.1% of deaths,
with the majority of this error generated when deaths
following AKI diagnosed using the study reference standard
were missed.
Sensitivity analyses
To study whether AKI misclassification occurs in other
populations excluded by our selection criteria, we performed
two sensitivity analyses. First, we examined subjects with a
known outpatient baseline value but only one inpatient
serum creatinine measurement available. This group, con-
sisting of 2996 patients, was excluded from the main analysis
because two of the three baseline creatinine estimation
methods studied require more than one measurement.
As expected, these subjects were low-risk patients with a
median outpatient baseline serum creatinine value of 0.94
(0.80,1.13) mg/dl, an overall 60-day mortality of 1.0%
(31/2996), and an AKI rate of 3.7% (N¼ 110). When using
an imputed estimate of baseline creatinine, we still observed
an overestimation of AKI incidence (15.3 versus 3.7% with
known baseline value; Po0.001). Secondly, we examined the
differences in AKI rates among the 10,477 patients without a
recorded outpatient serum creatinine value using the three
estimation methods; the study reference standard was not
computable in this population. Both imputed and minimum
methods still resulted in higher AKI rates (27.1 and 35.4%,
respectively) than when using the admission serum creatinine
value (12.1%).
DISCUSSION
Missing preadmission serum creatinine value is a recognized
problem in AKI research. Although the use of surrogate
measures for baseline renal function avoids selection bias, it
introduces a non-discoverable measurement error leading to
misclassification of both disease occurrence and prognosis.
The results of this study indicate that commonly used
measures to estimate baseline serum creatinine can lead to a
significant misclassification in AKI studies. Depending on the
surrogate selected, this misclassification can occur in both
directions – either underestimating or overestimating the
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Figure 1 |Mortality rates. (a) In-hospital mortality rates grouped
by baseline estimation method. X axis groups mortality rates by
maximal Acute Kidney Injury Network (AKIN) stage and further
stratifies by baseline estimation method used. Y axis plots the
corresponding mortality rates with 95% confidence intervals
shown. (b) Sixty-day mortality rates grouped by baseline
estimation method. X axis groups mortality rates by maximal
AKIN stage and further stratifies by baseline estimation method
used. Y axis plots the corresponding mortality rates with
95% confidence intervals shown.
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disease incidence, which, in turn, impacts the staging and
associated mortality of presumed AKI. If the proportion of
analyzed patients using surrogates is significant, the practice
could adversely affect the quality of study outcomes and
conclusions.
All three surrogates used in our study introduced
significant error. As the distribution of eGFRs in our
population was skewed toward lower values, imputing an
eGFR value of 75 ml/min per 1.73 m2 frequently overestimated
the actual eGFR. The net effect of imputation was to falsely
inflate AKI disease occurrence and staging. In populations
enriched with chronic kidney disease, including other
hospitalized populations, the elderly, and those with diabetes
or hypertension, applying this method would be expected to
consistently yield low specificity for detecting AKI and inflate
the probability of a type I error. The misclassification of AKI
led to a significant proportion of all deaths at 60 days being
falsely associated with AKI in our cohort (18.5%).
The use of inpatient creatinine measurements as surro-
gates for baseline function also resulted in misclassification.
Using a minimum serum creatinine value as a baseline also
inflated the disease incidence, indicating that the minimum
creatinine value was often lower than the most recent
outpatient creatinine value. Although the reasons for this are
not entirely clear, potential explanations include the effects of
aggressive volume expansion, discontinuance of renin–
angiotensin–aldosterone system (RAAS) blockade, or de-
creased creatinine generation in the midst of acute illness.17,18
Similar to imputation, the underestimation of baseline serum
creatinine value also led to a low specificity for diagnosing
AKI and misclassifying subsequent deaths.
In contrast to an imputed or minimum serum creatinine
value, use of the admission serum creatinine value as a
baseline resulted in nearly a 50% reduction in the reported
incidence of AKI compared with that using a known
outpatient baseline value. This decrease is perhaps best
explained by the missed diagnosis of community-acquired
AKI that improves or stabilizes during hospitalization. The
higher mortality rates observed when using this baseline
reflect the bias of using this method, which is only sensitive
to AKI that continues to worsen during hospitalization.
The use of surrogates for baseline renal function across
AKI studies has important implications for epidemiological
studies, clinical trial enrollment, and resource allocation. Use
of different surrogate baselines makes it difficult to compare
or summarize studies of AKI incidence and natural history,19
determine accurate power estimates for AKI treatment trials,
and further refine risk-prediction models for AKI-related
clinical outcomes. The specific impact of baseline choice on
the latter is particularly significant. For example, despite
obtaining similar 60-day mortality rates using various
surrogate estimates, we observed that many deaths were
misclassified as following AKI. The misclassification of deaths
could adversely effect the development of valid prediction
models for important AKI-associated outcomes as variations
in the baseline applied may capture a significantly different
group of patients. AKI studies using different surrogate
baselines may also not be directly comparable or readily
combined for meta-analysis. For example, baseline choice may
explain, in part, the observed difference in AKI rates in one
study comparing RIFLE and AKIN using the same cohort,12
whereas a separate study did not.4 Finally, although restricting
the diagnostic window of AKI to 48 h as recommended by the
current consensus criteria may ‘reduce the need for baseline’
renal function,9 this approach significantly reduces the
sensitivity to AKI starting before admission. These observations
suggest the need for additional criteria to better define the
contribution of preadmission renal injury to that currently
captured by the AKIN criteria.
Retrospective determination of a change in renal function
using serum creatinine value is the current metric for
diagnosing and staging AKI. This feature distinguishes it
from other acute diseases, including sepsis or the acute
respiratory distress syndrome, in which both injury (abnor-
mal chest X-ray, tissue cultures) and functional (WBC count,
oxygenation) markers are required to satisfy the diagnostic
criteria.20,21 Further, as the relationship between serum
creatinine and actual GFR is nonlinear, quantification of
injury severity will continue to rely on the reference
point as much as the observed difference. This limitation
continues to confront the study of AKI, although current
efforts to identify novel and promising candidate markers
that are able to reflect the nature of injury, such as neutrophil
gelatinase-associated lipocalin22 or kidney injury molecule-
1,23 may introduce a much-needed segregation between
evolving injury and ongoing changes in function.
This study has some limitations. By design, the study
selected patients with at least one preadmission serum
creatinine measurement in the previous year and two serum
creatinine measurements during hospitalization, and excluded
patients with fewer measured creatinine values or ones
measured at a laboratory outside VUMC. The selection
criteria may have skewed the population to one that is more
chronically ill. However, in the sensitivity analyses examining
patients without a baseline serum creatinine value and patients
with one inpatient creatinine value, the three methods still
disagreed on AKI classification, suggesting that the use of
surrogates would introduce a significant error in populations
not included in the main analysis. Secondly, we did not use
timed urine output criteria for diagnosing AKI because the
hourly urine output data required to determine oliguria within
any 6, 12, or 24 h window was not reliably captured in a non-
ICU setting. The lack of accurate urine output data replicates
the situation at most US hospitals, and recent data suggest that
urine output data may not add materially to AKIN risk
prediction when compared with serum creatinine concentra-
tion alone.3 Whether urine output adds discrimination to
certain subpopulations, including those with subtle injury
or those with extremely low baseline creatinine values
(o0.5 mg/dl), for example, remains to be determined.
In conclusion, frequently used methods to estimate
baseline kidney function do not closely agree and result in
540 Kidney International (2010) 77, 536–542
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bidirectional misclassification of AKI incidence, severity, and
prognosis in a large, broadly selected hospital population.
The use of different estimates may introduce a significant
measurement error adversely impacting the quality of
individual AKI studies, as well as continue to hinder
comparison of studies between settings. These findings
underscore the need for additional consensus criteria to
better characterize preadmission AKI by specifying a standard
method to incorporate previously known baseline data. It
also suggests the need to develop better methods to estimate
baseline kidney function when a preadmission serum
creatinine is truly missing. The development and validation
of improved surrogates would significantly improve the
fidelity of future studies of AKI diagnosis and prognosis.
MATERIALS AND METHODS
Study population
Adult patients (X18 years old) were eligible for this study if
admitted to the Vanderbilt University Hospital for a minimum of 24
continuous hours between 10 January 2007 and 10 January 2008. As
the main adult inpatient facility within VUMC Hospital, Vanderbilt
University Hospital is a large tertiary referral center serving middle
Tennessee and the surrounding areas. Inclusion criteria requirement
was that a patient should have at least two inpatient SCr
measurements within the first 7 days of hospitalization and at least
one outpatient nonemergency room SCr measured between 7 and
365 days before admission available within the VUMC laboratory
database. The study excluded patients with previous evidence of
stage 5 chronic kidney disease or end-stage renal disease, based on
the previous International Statistical Classification of Diseases and
Related Health Problems Ninth Edition (ICD-9) code assignment of
585.6, 996.73, 996.68, 996.56, 792.5, or 458.21, or an earlier
outpatient baseline-calculated eGFR of o15 ml/min per 1.73 m2.
The study included data from the first hospitalization for patients
with multiple admissions during the study interval.
Data collection
General demographic information (e.g., age, gender, race, admitting
service, and location) and laboratory data were collected from the
institutional electronic medical record, which serves inpatients and
outpatients at VUMC. Data on SCr measurements were retrieved for
each eligible patient for a period of 1 year before admission if
available. The baseline outpatient serum creatinine value was
defined as the most recent outpatient nonemergency room
measurement between 7 and 365 days before hospitalization. This
was chosen as our reference standard as it was felt to approximate
the approach most often applied by clinicians when evaluating a
patient in the acute setting with potential AKI. Information on
comorbid conditions was identified using the corresponding ICD-9
codes for diabetes mellitus, hypertension, coronary artery disease,
congestive heart failure, and peripheral vascular disease assigned
before admission (Appendix 1). Chronic kidney disease was defined
as using ICD-9 codes (see Appendix) or a calculated eGFRo60 ml/
min per 1.73 m2 from the baseline outpatient SCr value. Differences
in demographic, comorbidity, and admission data between subjects
with outpatient Scr data and those with only previous inpatient or
no baseline SCr data were analyzed to address potential information
bias. The VUMC Institutional Review Board approved the study
protocol.
Assessment of AKI using different baseline values and other
outcomes of interest
To diagnose and stage AKI, we compared changes in SCr values
between estimated or established baseline values and the peak
inpatient value within the first 7 days of hospitalization using the
AKIN criteria.9 Stage I injury was defined by an increase of
X0.3 mg/dl or 50% increase from baseline, Stage II as a4200–300%
increase from baseline, and Stage III by an increase in SCr to
4300% from baseline, an SCr of X4.0 mg/dl with an increase of at
least 0.5 mg/dl, or the receipt of renal replacement therapy. SCr
measurements within 24 h before the administrative admission time
were included to capture early creatinine values drawn from the
emergency room or from acute visits prompting subsequent
admission. We required a minimum 50% increase in SCr when
defining AKIN stage III for patients receiving acute dialysis to favor
inclusion of subjects receiving dialysis for AKI rather for acute
intoxication without AKI.
The following four variables were derived from the cohort data
to evaluate the methods of detecting AKI occurrence: (1) an
outpatient baseline serum creatinine, which served as a reference
standard for all comparisons; (2) an imputed serum creatinine based
on an assumed baseline eGFR of 75 ml/min per 1.73 m2, which is
recommended by the Acute Dialysis Quality Initiative; (3) the
minimum serum creatinine available during the first 7 days of
hospitalization; and (4) the first serum creatinine value available
during hospital admission. eGFR for all outpatient and surrogate
SCr measures was derived using the abbreviated modification
of diet and renal disease equation (GFR (ml/min per
1.73 m2)¼ 186 (SCr)1.154 (age)0.203 (0.742 if female)
(1.210 if African–American) (conventional units)).
Acute dialysis was captured using hospital discharge current
procedural terminology (CPT) codes 90935, 90937, 90945, 90947,
90989, 90993, 90921, and 90925 assigned within the first 7 days of
hospitalization. A board-certified nephrologist (EDS) validated the
AKIN staging algorithm by auditing 20 randomly selected patients
who met the criteria for each AKIN stage and 20 patients who were
not defined as having AKI using each of the four baseline definitions
(320 evaluations total). In-hospital death was measured by
retrieving the ‘discharge status’ field of the administrative database
for the hospital. Sixty-day mortality rates were calculated by linking
the Social Security Death Index to the study data using social
security number, date of birth, and patient name. Social Security
Death Index data were updated to the latest version published by the
Social Security Administration as of June 2009.
Statistical analysis
For this descriptive study, frequencies were reported as percentages
and groups were compared using the Pearson’s w2 test or the Fisher
exact test. Continuous variables were compared using Student’s t-test
or the Wilcoxon Rank Sum test, as determined by the underlying data
distribution. Percent misclassification was calculated by comparing
AKIN staging based on known baseline SCr compared with AKIN
staging using each of the methods used for estimating baseline kidney
function. Sensitivities and specificities for the diagnosis of AKI were
calculated for each surrogate method using the outpatient serum
creatinine as a study reference standard. Misclassification of
60-day mortality was defined as the sum of deaths after a false-
positive diagnosis of AKI and deaths after a false-negative diagnosis of
AKI divided by total deaths. Two-tailed P-values of o0.05 were
considered to be statistically significant. All analyses were performed
using SAS.
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Appendix 1
ICD9 and current procedural terminology codes used to
define patient conditions
Chronic kidney disease:
250.4, 585, 585.1, 585.2, 585.3, 585.4, 585.5, 585.9, 403.*,
580*, 581.*, 582.*, 583.*
Congestive heart failure:
428.*, 402.01, 402.11, 402.91
Hypertension:
401.*, 402.*, 403.*, 404.*, 405.*
Diabetes mellitus:
250.*, 249.*, 648
Coronary artery disease:
414.*, 410.*, 412, 411.0, 411.1, 411.8
Peripheral vascular disease:
440.*
Liver disease:
572.*, 571.* except 571.1, 571.0
Acute dialysis (current procedural terminology) codes:
90935, 90937, 90945, 90947, 90989, 90993, 90921, 90925
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